GIS:FRA
Gilead Sciences, Inc
152,66 €
arrow_downward
-0,35%(-0,54) 1 d.
13. nov., 22:00:00 GMT+1 · EUR
search
Visi simboli
| Simbols | Cena | Izmaiņas | % izmaiņu |
|---|
insights_autoNotiek galveno ieskatu ģenerēšana par šādu tēmu: GIS…
Atvērt
151,14 €
Augsta
152,66 €
Zema
151,14 €
Tirgus kapitalizācija
208,48 mljrd.
Vid. apjoms
224,00
Apjoms
56,00
Augstākā 52 ned.
157,14 €
Zemākā 52 ned.
100,42 €
Darbinieku skaits
17 tūkst.
Atvērt
151,14 €
Augsta
152,66 €
Zema
151,14 €
Tirgus kapitalizācija
208,48 mljrd.
Vid. apjoms
224,00
Apjoms
56,00
Augstākā 52 ned.
157,14 €
Zemākā 52 ned.
100,42 €
Darbinieku skaits
17 tūkst.
Ziņas un raksti
No tīmekļa avotiem un ziņu partneriem
CoinMarketCap
·
pirms 5 stundām
Gilead Sciences tokenized stock (xStock) Price History and Historical Data
Zacks Investment Research
·
pirms 1 dienas
Top Research Reports for Home Depot, Gilead & TotalEnergies
The Globe and Mail
·
pirms 1 dienas
Can Gilead Sciences' HIV Business Fuel Sustainable Long-Term Growth?
Investing.com
·
pirms 1 dienas
Argus raises Gilead Sciences stock price target on pipeline strength
Profils
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19. It also develops medicines in therapeutic areas such as oncology and inflammation and cell therapy.
In 1987, Michael L. Riordan founded the company under the name Oligogen. The original name was a reference to oligonucleotides, small strands of DNA used to target genetic sequences. Gilead held its initial public offering in 1992, and successfully developed drugs including Tamiflu and Vistide that decade.
In the 2000s, Gilead began evolving from a biotechnology company into a large pharmaceutical company, through acquisitions and investments, acquiring several subsidiaries. Gilead is a member of the Nasdaq-100 and the S&P 100.
The company has faced criticism over its business practices, including extremely high pricing of drugs such as Sovaldi and Truvada in the United States relative to production cost and cost in the developing world. Wikipedia
Par “Gilead Sciences, Inc”
ĢenerāldirektorsDaniel O'Day
Darbinieki17 tūkst.
Dibināšanas datums1987. gada 22. jūn.
Galvenais birojsFoster City, Kalifornija, Amerikas Savienotās Valstis
SektorsHealth Care
Nozare-
Tīmekļa vietnegilead.com